Prosensa Debuts On The Nasdaq Hours After Getting Breakthrough Designation For Lead Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
The Dutch biotech raised $78 million in an initial public offering, peaking investors’ interest with a breakthrough designation for its lead drug candidate, partnered with GSK.